Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 15/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301499 | 1.00 | METTL3 (0.56) | METTL3CSF1REGFRERBB2RIPK1 | |
| SCHEMBL1301788 | 0.89 | METTL3 (0.59) | METTL3CSF1REGFR | |
| SCHEMBL1301791 | 0.89 | METTL3 (0.59) | METTL3CSF1REGFR | |
| SCHEMBL12108311 | 0.88 | METTL3 (0.58) | METTL3CSF1REGFR | |
| SCHEMBL12108366 | 0.88 | METTL3 (0.59) | METTL3 | |
| SCHEMBL1301310 | 0.86 | METTL3 (0.46) | METTL3CSF1REGFRERBB2 | |
| SCHEMBL1301395 | 0.86 | METTL3 (0.46) | METTL3EGFR | |
| SCHEMBL1301309 | 0.86 | METTL3 (0.46) | METTL3CSF1REGFRERBB2 | |
| SCHEMBL1301400 | 0.86 | METTL3 (0.46) | METTL3EGFR | |
| SCHEMBL12107926 | 0.85 | METTL3 (0.72) | METTL3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885CSF1R 4217/4885EGFR 4552/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885CSF1R 4217/4885EGFR 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.